Marcella C. A. Muller

Dr. Marcella C. A. Muller

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
SMSaskia Middeldorp
Saskia Middeldorp
MCMichiel Coppens
Michiel Coppens
THThijs F. van Haaps
Thijs F. van Haaps
MFMerijn Foppen
Merijn Foppen
AVAlexander P. J. Vlaar
Alexander P. J. Vlaar
NENick van Es
Nick van Es
Coronavirus disease 2019 (COVID‐19) can lead to systemic coagulation activation and thrombotic complications. We investigated the incidence of objectively confirmed venous thromboembolism (VTE) in 198 hospitalized patients with COVID‐19 in a single‐center cohort study. Seventy‐five patients (38%) were admitted to the intensive care unit (ICU). At time of data collection, 16 (8%) were still hospitalized and 19% had died. During a median follow‐up of 7 days (IQR, 3‐13), 39 patients (20%) were diagnosed with VTE of whom 25 (13%) had symptomatic VTE, despite routine thrombosis prophylaxis. The cumulative incidences of VTE at 7, 14 and 21 days were 16% (95% CI, 10‐22), 33% (95% CI, 23‐43) and 42% (95% CI 30‐54) respectively. For symptomatic VTE, these were 10% (95% CI, 5.8‐16), 21% (95% CI, 14‐30) and 25% (95% CI 16‐36). VTE appeared to be associated with death (adjusted HR, 2.4; 95% CI, 1.02‐5.5). The cumulative incidence of VTE was higher in the ICU (26% (95% CI, 17‐37), 47% (95% CI, 34‐58), and 59% (95% CI, 42‐72) at 7, 14 and 21 days) than on the wards (any VTE and symptomatic VTE 5.8% (95% CI, 1.4‐15), 9.2% (95% CI, 2.6‐21), and 9.2% (2.6‐21) at 7, 14, and 21 days). The observed risk for VTE in COVID‐19 is high, particularly in ICU patients, which should lead to a high level of clinical suspicion and low threshold for diagnostic imaging for DVT or PE. Future research should focus on optimal diagnostic and prophylactic strategies to prevent VTE and potentially improve survival.

28 May 2024 in Critical Care
Verified
Journal Article
Open access
PDF file
MSMarleen A. Slim
Marleen A. Slim
NMNiels van Mourik
Niels van Mourik
LBLieke Bakkerus
Lieke Bakkerus
KFKatherine Fuller
Katherine Fuller
LALydia Acharya
Lydia Acharya
LVLonneke A. van Vught
Lonneke A. van Vught
Despite significant progress in our understanding of the pathophysiology of sepsis and extensive clinical research, there are few proven therapies addressing the underlying immune dysregulation of this life-threatening condition. The aim of this scoping review is to describe the literature evaluating immunotherapy in adult patients with sepsis, emphasizing on methods providing a “personalized immunotherapy” approach, which was defined as the classification of patients into a distinct subgroup or subphenotype, in which a patient’s immune profile is used to guide treatment. Subgroups are subsets of sepsis patients, based on any cut-off in a variable. Subphenotypes are subgroups that can be reliably discriminated from other subgroup based on data-driven assessments. Included studies were randomized controlled trials and cohort studies investigating immunomodulatory therapies in adults with sepsis. Studies were identified by searching PubMed, Embase, Cochrane CENTRAL and ClinicalTrials.gov, from the first paper available until January 29th, 2024. The search resulted in 15,853 studies. Title and abstract screening resulted in 1409 studies (9%), assessed for eligibility; 771 studies were included, of which 282 (37%) were observational and 489 (63%) interventional. Treatment groups included were treatments targeting the innate immune response, the complement system, coagulation and endothelial dysfunction, non-pharmalogical treatment, pleiotropic drugs, immunonutrition, concomitant treatments, Traditional Chinese Medicine, immunostimulatory cytokines and growth factors, intravenous immunoglobulins, mesenchymal stem cells and immune-checkpoint inhibitors. A personalized approach was incorporated in 70 studies (9%). Enrichment was applied using cut-offs in temperature, laboratory, biomarker or genetic variables. Trials often showed conflicting results, possibly due to the lack of patient stratification or the potential influence of severity and timing on immunomodulatory therapy results. When a personalized approach was applied, trends of clinical benefit for several interventions emerged, which hold promise for future clinical trials using personalized immunotherapy.

29 November 2025 in Journal of Vascular Surgery: Venous and Lymphatic Disorders
Verified
Journal Article
Open access
LOLaurens A. Oomen
Laurens A. Oomen
JDJanette van Diest
Janette van Diest
FLFelice R.M. Lucas
Felice R.M. Lucas
JRJitske Rijpkema
Jitske Rijpkema
GBGeorge L. Burchell
George L. Burchell
PTPieter R. Tuinman
Pieter R. Tuinman
Catheter-related thrombosis (CRT) is a known complication of central venous catheters and peripherally inserted central catheters, yet optimal treatment remains uncertain. We conducted a systematic review and national survey to assess current CRT management strategies. Following the PRISMA guidelines, we searched three databases through October 2024 for studies on CRT associated with central venous catheters or peripherally inserted central catheters. Meta-analyses and subgroup analyses were performed by anticoagulant type. A national survey among Dutch intensive care and hematology physicians explored current treatment practices. Of 4123 records screened, 34 observational studies were included, mostly involving patients with cancer. The venous thromboembolism recurrence rate per 100 patient-years was higher in patients with cancer (14.1; 95% confidence interval, 11.4- 17.4; I2 = 35.1) vs patients without cancer (2.0; 95% confidence interval, 0.6-6.0; I2 = 10.3; P = .0002). Recurrence was comparable between direct oral anticoagulants (DOACs) and low-molecular-weight heparin/vitamin K antagonists (LMWH/VKAs), at 11.0 vs 7.6 (P = .14). Major bleeding occurred in 10.5 vs 13.1 (P = .45), and clinically relevant nonmajor bleeding in 26.2 vs. 22.4 (P = .70), for DOACs vs LMWH/VKAs, respectively. All studies were observational, most at high risk of bias. Survey data showed LMWH was preferred for symptomatic CRT (50%), with treatment lasting 8 days to 6 months. In asymptomatic CRT, anticoagulant type and duration were left to physician discretion in 64% of cases. Treatment with LMWH/VKA or DOACs shows similarly low venous thromboembolism recurrence, although rates are higher in patients with cancer. Bleeding was substantial and comparable across therapies. Evidence is limited by observational bias. Survey data show that LMWH predominates for CRT, with variable duration. Well-designed randomized controlled trials are warranted.

14 November 2024 in Critical Care Explorations
Verified
Journal Article
Open access
MSMarleen A. Slim
Marleen A. Slim
RARombout B. E. van Amstel
Rombout B. E. van Amstel
MMMarcella C. A. Muller
Marcella C. A. Muller
OCOlaf L. Cremer
Olaf L. Cremer
AVAlexander P. J. Vlaar
Alexander P. J. Vlaar
MCMARS Consortium
MARS Consortium
OBJECTIVES: Sepsis is an evolving process and proposed subtypes may change over time. We hypothesized that previously established sepsis subtypes are dynamic, prognostic of outcome, and trajectories are associated with host response alterations. DESIGN: A secondary analysis of two observational critically ill sepsis cohorts: the Molecular diAgnosis and Risk stratification of Sepsis (MARS) and the Medical Information Mart for Intensive Care-IV (MIMIC-IV). SETTING: ICUs in the Netherlands and United States between 2011–2014 and 2008–2019, respectively. PARTICIPANTS: Patient admission fulfilling the Sepsis-3 criteria upon ICU admission adjudicated to one of four previously identified subtypes, comprising 2,416 admissions in MARS and 10,745 in MIMIC-IV. MAIN OUTCOMES AND MEASURES: Subtype stability and the changes per subtype on days 2, 4 and 7 of ICU admission were assessed. Next, the associated between change in clinical subtype and outcome and host response alterations. RESULTS: In MARS, upon ICU admission, 6% (n = 150) of the patient admissions were α-type, 3% (n = 70) β-type, 55% (n = 1317) γ-type, and 36% (n = 879) δ-type; in MIMIC-IV, this was α = 22% (n = 2398), β = 22% (n = 2365), γ = 31% (n = 3296), and δ = 25% (2686). Overall, prevalence of subtypes was stable over days 2, 4, and 7. However, 28–56% (MARS/MIMIC-IV) changed from α on ICU admission to any of the other subtypes on day 2, 33–71% from β, 57–32% from γ, and 50–48% from δ. On day 4, overall subtype persistence was 33–36%. γ or δ admissions remaining in, or transitioning to, subtype γ on days 2, 4, and 7 exhibited lower mortality rates compared with those remaining in, or transitioning to, subtype δ. Longitudinal host response biomarkers reflecting inflammation, coagulation, and endothelial dysfunction were most altered in the δ-δ group, followed by the γ-δ group, independent of the day or biomarker domain. CONCLUSIONS AND RELEVANCE: In two large cohorts, subtype change to δ was associated with worse clinical outcome and more aberrant biomarkers reflecting inflammation, coagulation, and endothelial dysfunction. These findings underscore the importance of monitoring sepsis subtypes and their linked host responses for improved prognostication and personalized treatment strategies.

1 June 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
HOHendrikus J.A. van Os
Hendrikus J.A. van Os
DVDagmar Verbaan
Dagmar Verbaan
YRYnte Ruigrok
Ynte Ruigrok
PDPaul Dennesen
Paul Dennesen
MMMarcella C. A. Muller
Marcella C. A. Muller
MWMarieke J.H. Wermer
Marieke J.H. Wermer
Background: Young patients with aneurysmal subarachnoid hemorrhage (aSAH) and a history of migraine may have an increased risk of delayed cerebral ischemia. We investigated this potential association in a prospective cohort of aSAH patients under 50 years of age. Methods: In our prospective cohort study, we included patients with aSAH under 50 years of age from 3 hospitals in the Netherlands. We assessed lifetime migraine history with a short screener. Delayed cerebral ischemia was defined as neurological deterioration lasting >1 hour not attributable to other causes by diagnostic workup. Adjustments were made for possible confounders in multivariable Cox regression analyses, and adjusted hazard ratios were calculated. Results: We included 236 young aSAH patients (mean age, 41 years; 64% women) of whom 44 (19%) had a history of migraine (16 with aura). Patients with aSAH and a history of migraine were not at increased risk of developing delayed cerebral ischemia compared with patients without migraine (25% versus 20%; adjusted hazard ratio, 1.16 [95% CI, 0.57–2.35]). Additionally, no increased risk was found in migraine patients with aura (adjusted hazard ratio, 0.85 [95% CI, 0.30–2.44]) or in women (adjusted hazard ratio, 1.24 [95% CI, 0.58–2.68]). Conclusions: Patients with aSAH under the age of 50 years with a history of migraine are not at increased risk of delayed cerebral ischemia.

25 September 2025 in Critical Care Medicine
Verified
Journal Article
Open access
SWStefan Franciscus van Wonderen
Stefan Franciscus van Wonderen
SRSenta Jorinde Raasveld
Senta Jorinde Raasveld
AFAndrew W J Flint
Andrew W J Flint
JSJimmy Schenk
Jimmy Schenk
COClaudia van Den Oord
Claudia van Den Oord
IGInPUT Study Group
InPUT Study Group
Objective: There is a lack of comprehensive international data regarding platelet transfusion practices in the ICU. This study aimed to evaluate the current occurrence rate of platelet transfusion in the ICU and provide an overview of platelet transfusion practices including indications for a platelet transfusion, thresholds, (non-)adherence and geo-economic region variations. Design: International prospective cohort study. Setting: Two hundred thirty-three centers in 30 countries worldwide. Patients: All patients 18 years old and older, admitted to the ICU during a single study week, selected by each site from one of the 16 predefined weeks (March 2019 to October 2022), were included. Interventions: None. Measurements and Main Results: Of the 3643 patients, 208 (6%) received a platelet transfusion during their ICU stay and main indications consisted of active bleeding (42%, n = 187/443), prophylaxis (33%, n = 144/443) or an upcoming procedure (12%, n = 51/443). The median platelet count before transfusion was 44 × 10 9 /L (interquartile range [IQR], 20–78) with variation by indication, including a higher median of 60 × 10 9 /L (IQR 31–93) during active bleeding. A threshold for transfusion was stated in 51% ( n = 224/443) of the events, with a median threshold platelet count of 50 × 10 9 /L (IQR, 40–100). The advised threshold was not adhered to in 16% ( n = 36/224) of cases, with the majority having active bleeding as indication. Contrasts in transfusion practices were observed across different geo-economic regions. Platelet transfusions were administered to 6% ( n = 156/2520) of patients in high-income countries, 5% ( n = 52/1069) of patients in upper-middle-income countries and in none from lower-middle-income countries ( n = 0/54). Non-adherence was higher in the high-income countries (23%, n = 34/149) than upper-middle-income countries (3%, n = 2/75). Conclusions: Platelet transfusions were administered to a small proportion of critically ill patients, and were given to treat active bleeding or as prophylaxis in the majority of cases. Occurence rate, indication and threshold adherence for platelet transfusion widely varied between geo-economic regions.